Program
zorevunersen
Also written as “zorevunersen (STK-001)”, “STK-001 - Single Ascending Doses” and “STK-001 - Multiple Ascending Doses”.
Its studies are mostly in Epilepsies, Myoclonic, led by Stoke Therapeutics.
Furthest: phase 3, since Mar 6, 20253 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Stoke Therapeutics | 32 open or running | phase 3since Mar 6, 2025 | Jun 8, 2020 | Mar 2027phase 3 · NCT06872125 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 8, 2020First study: phase 2 study in Epilepsies, MyoclonicFirst studyNCT04442295 · 62 enrolled · United States
- Feb 2, 2021Phase 2 study in Epilepsies, MyoclonicNCT04740476 · 60 enrolled · United States
- Mar 6, 2025Phase 3 study in Epilepsies, MyoclonicNCT06872125 · 170 enrolled · United States, China, France and more
Ahead
- Mar 2027Primary completion: phase 3 study in Epilepsies, MyoclonicNCT06872125
- Mar 31, 2029Primary completion: phase 2 study in Epilepsies, MyoclonicNCT04740476
TargetBeta
SCN1A →read by rule
“Zorevunersen is an antisense oligonucleotide (ASO) that is intended to increase the level of productive SCN1A messenger RNA (mRNA) and consequently increase the expression of the sodium channel Nav1.1 protein.”study text, by rule · the study
Other programs on SCN1A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lidocainerule | Keenova Therapeutics | phase 4 | 63 |
| Lamotriginerule | GlaxoSmithKline | phase 4 | 61 |
| Carbamazepinerule | grin-therapeutics-inc | phase 4 | 21 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| chloroprocainerule | sintetica-sa | phase 4 | 8 |
| Riluzolerule | Sanofi | phase 4 | 6 |
| Prilocainerule | Haisco Pharmaceutical Group | phase 4 | 2 |
| Carticainerule | Laboratoires Thea | phase 4 | 1 |
| Ropivacainerule | painreform-ltd | phase 3 | 17 |
| Phenytoinrule | Viatris | phase 3 | 10 |
| rufinamiderule | Eisai | phase 3 | 7 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06872125Epilepsies, Myoclonic · United States, China, France and more | 3 | Active, not recruiting | Mar 2027 | 170 |
| NCT04740476Epilepsies, Myoclonic · United States | 2 | Active, not recruiting | Mar 31, 2029 | 60 |
| NCT04442295Epilepsies, Myoclonic · United States | 2 | Completed | Nov 14, 2023 | 62 |
How it is read
Names in the registry
- “zorevunersen”, 1 entry
- “zorevunersen (STK-001)”, 1 entry
- “STK-001 - Single Ascending Doses”, 1 entry
- “STK-001 - Multiple Ascending Doses”, 1 entry
Conditions, from the studies’ own filings
- Epilepsies, Myoclonic, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.